Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)

References

• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
   PubMed Web of Science ®Google Scholar
• LambertsMStaerkLOlesenJBMajor bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patientsJ Am Heart Assoc201762 piie00451728196815
   PubMedGoogle Scholar
• SharmaMCorneliusVRPatelJPDaviesJGMolokhiaMEfficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysisCirculation2015132319420425995317
   PubMed Web of Science ®Google Scholar
• BaiYGuoSDDengHEffectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysisAge Ageing201847191728985259
   PubMed Web of Science ®Google Scholar
• ChughSSHavmoellerRNarayananKWorldwide epidemiology of atrial fibrillation: a global burden of disease 2010 studyCirculation2014129883784724345399
   PubMed Web of Science ®Google Scholar
• KimISKimHJKimTHNon-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysisJ Cardiol201872210511229519547
   PubMed Web of Science ®Google Scholar
• SchulmanSAngeråsUBergqvistDSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisDefinition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJ Thromb Haemost2010820220419878532
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisDefinition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patientsJ Thromb Haemost2005369269415842354
   PubMed Web of Science ®Google Scholar
• ParmeleePAThurasPDKatzIRLawtonMPValidation of the cumulative illness rating scale in a geriatric residential populationJ Am Geriatr Soc19954321301377836636
   PubMed Web of Science ®Google Scholar
• LipGYHHalperinJLImproving stroke risk stratification in atrial fibrillationAm J Med2010123648448820569748
   PubMed Web of Science ®Google Scholar
• LipGYFrisonLHalperinJLLaneDAComparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) scoreJ Am Coll Cardiol201157217318021111555
   PubMed Web of Science ®Google Scholar
• CockcroftDWGaultHPrediction of creatinine clearance from serum creatinineNephron197616131411244564
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJARISTOTLE Committees and InvestigatorsApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• BarcoSCheungYWEikelboomJWCoppensMNew oral anticoagulants in elderly patientsBest Pract Res Clin Haematol201326221522423953909
   PubMed Web of Science ®Google Scholar
• ColemanCIAntzMBowrinKReal-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US studyCurr Med Res Opin201632122047205327633045
   PubMed Web of Science ®Google Scholar
• LipGYKeshishianAKambleSReal-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisThromb Haemost2016116597598627538358
   PubMed Web of Science ®Google Scholar
• LarsenTBSkjøthFNielsenPBKjældgaardJNLipGYComparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyBMJ2016353i318927312796
   PubMed Web of Science ®Google Scholar
• StaerkLFosbølELLipGYHIschaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort studyEur Heart J2017381290791527742807
   PubMed Web of Science ®Google Scholar
• ForslundTWettermarkBAndersenMHjemdahiPStroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort studyEuropace201820342042828177459
   PubMed Web of Science ®Google Scholar
• AminAKeshishianATrocioJRisk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare populationCurr Med Res Opin20173391595160428635338
   PubMed Web of Science ®Google Scholar
• KrumholzHMPost-hospital syndrome – an acquired, transient condition of generalized riskN Engl J Med2013368210010223301730
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMESC Scientific Document Group. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summaryEur Heart J201738272137214927282612
   PubMed Web of Science ®Google Scholar
• GiustozziMVedovatiMCVerdecchiaPVitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-lifeEur J Intern Med201633424627394924
   PubMed Web of Science ®Google Scholar
• BarraMEFanikosJConnorsJMEvaluation of dose-reduced direct oral anticoagulant therapyAm J Med2016129111198120427341955
   PubMed Web of Science ®Google Scholar
• AlexanderJHAnderssonULopesRDApixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) InvestigatorsApixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trialJAMA Cardiol20161667368127463942
   PubMed Web of Science ®Google Scholar
• SteinbergBAShraderPPieperKOutcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) II InvestigatorsFrequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)J Am Heart Assoc20187 piie00763329453305
   PubMed Web of Science ®Google Scholar
• YaoXShahNDSangaralinghamLRGershBJNoseworthyPANon-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunctionJ Am Coll Cardiol201769232779279028595692
   PubMed Web of Science ®Google Scholar
• LiXKeshishianAHamiltonMApixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approachPLoS One2018131e019172229373602
   PubMed Web of Science ®Google Scholar
• PlsekPEGreenhalghTComplexity science: the challenge of complexity in health careBMJ2001323731362562811557716
   PubMed Web of Science ®Google Scholar